Tumor mutational burden (TMB), defined as the number of somatic mutations per megabase
of interrogated genomic sequence, varies across malignancies. Panel sequencing–based …

Primary lung cancer remains the most common malignancy after non-melanocytic skin
cancer, and deaths from lung cancer exceed those from any other malignancy worldwide [1] …

Background High tumor mutation burden (TMB-H) has been proposed as a predictive
biomarker for response to immune checkpoint blockade (ICB), largely due to the potential for …

Background Tumor mutational burden (TMB), defined as the number of somatic mutations
per megabase of interrogated genomic sequence, demonstrates predictive biomarker …

A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …

Immune checkpoint inhibitor (ICI) therapies have revolutionized the management of patients
with NSCLC and have led to unprecedented improvements in response rates and survival in …

Background Tumor mutational burden (TMB) measurements aid in identifying patients who
are likely to benefit from immunotherapy; however, there is empirical variability across panel …

The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one
of the main achievements of translational research in the latest years. In the modern clinical …

A growing number of druggable targets and national initiatives for precision oncology
necessitate broad genomic profiling for many cancer patients. Whole exome sequencing …

Cancer of unknown primary has a dismal prognosis, especially following failure of platinum-
based chemotherapy. 10-20% of patients have a high tumor mutational burden (TMB), which …